Generic Giazo Availability
Last updated on Oct 9, 2024.
Giazo is a brand name of balsalazide, approved by the FDA in the following formulation(s):
GIAZO (balsalazide disodium - tablet;oral)
-
Manufacturer: VALEANT PHARMS INTL
Approval date: February 3, 2012
Strength(s): 1.1GM (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Giazo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 7,452,872
Patent expiration dates:
- August 24, 2026✓
- August 24, 2026
-
Patent 7,625,884
Patent expiration dates:
- August 24, 2026✓
- August 24, 2026
-
Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
Patent 8,497,256
Issued: July 30, 2013
Inventor(s): Forbes William & Bortey Enoch & Johnson Lorin
Assignee(s): Salix Pharmaceuticals, LtdThe instant application provides methods and compositions for the treatment of male subjects having ulcerative colitis.
Patent expiration dates:
- June 23, 2031✓
- June 23, 2031
-
Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Patent 9,192,616
Issued: November 24, 2015
Inventor(s): Johnson Lorin
Assignee(s): Salix Pharmaceuticals, Inc.A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.
Patent expiration dates:
- August 2, 2026✓
- August 2, 2026
More about Giazo (balsalazide)
- Giazo consumer information
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: 5-aminosalicylates
- Breastfeeding
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.